Dymon Asia Capital (Singapore)’s AbbVie ABBV Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,800	Closed	-$2.04M	–	220
2025 Q3	$2.04M	Sell	8,800 -1,200	-12%	-$244K	0.21%	102
2025 Q2	$1.86M	Buy	10,000 +2,000	+25%	+$372K	0.26%	79
2025 Q1	$1.68M	Buy	8,000 +2,000	+33%	+$389K	0.37%	65
2024 Q4	$1.07M	Buy	+6,000	New	+$1.1M	0.25%	71
2024 Q2	–	Sell	-6,700	Closed	-$1.22M	–	96
2024 Q1	$1.22M	Buy	+6,700	New	+$1.15M	0.27%	68

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s ABBV Position: Q4 2025 in Review

Dymon Asia Capital (Singapore) sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 8,800 shares — an estimated $2.04M sold.

Dymon Asia Capital (Singapore) first reported a position in ABBV in Q1 2024 and held it in 5 quarters. The position peaked at $2.04M in Q3 2025. 4,156 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Dymon Asia Capital (Singapore) reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
Dymon Asia Capital (Singapore) sold 8,800 AbbVie shares in Q4 2025, an estimated $2.04M.
Dymon Asia Capital (Singapore) first reported a position in AbbVie in Q1 2024 and held it in 5 quarters.
Dymon Asia Capital (Singapore)'s AbbVie position peaked at $2.04M in Q3 2025.
4,156 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q4 2025, filed 13 Feb 2026.